Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2008 1
2009 1
2010 1
2011 1
2014 1
2015 1
2016 3
2017 2
2018 3
2019 2
2020 2
2021 2
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: sabatelli l. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12. Ann Hematol. 2023. PMID: 37171597 Free PMC article.
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: sabatelli l. Ann Hematol. 2023 Sep;102(9):2643-2644. doi: 10.1007/s00277-023-05321-3. Ann Hematol. 2023. PMID: 37432417 Free PMC article. No abstract available.
Access-site hematoma in distal and conventional transradial access: a randomized trial.
Lucreziotti S, Persampieri S, Gentile D, Barbieri L, Salerno-Uriarte D, Valli F, Sabatelli L, Panzacchi G, Centola M, Carugo S. Lucreziotti S, et al. Among authors: sabatelli l. Minerva Cardiol Angiol. 2022 Apr;70(2):129-137. doi: 10.23736/S2724-5683.21.05483-9. Epub 2021 Mar 11. Minerva Cardiol Angiol. 2022. PMID: 33703855 Clinical Trial.
Uric acid associated with acute heart failure presentation in Acute Coronary Syndrome patients.
Rebora P, Centola M, Morici N, Sacco A, Occhino G, Viola G, Oreglia J, Castini D, Persampieri S, Sabatelli L, Ferrante G, Lucreziotti S, Carugo S, Valsecchi MG, Oliva F, Giannattasio C, Maloberti A. Rebora P, et al. Among authors: sabatelli l. Eur J Intern Med. 2022 May;99:30-37. doi: 10.1016/j.ejim.2022.01.018. Epub 2022 Jan 17. Eur J Intern Med. 2022. PMID: 35058146
25 results